日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Real-world outcomes of trastuzumab deruxtecan as second- or further-line treatment in patients with HER2-mutant metastatic non-small cell lung cancer: a retrospective study

曲妥珠单抗德鲁替康作为HER2突变转移性非小细胞肺癌患者二线或后续治疗的真实世界疗效:一项回顾性研究

Huang, Kuofang; Hu, Zhihuang; Pan, Shifei; Qian, Jialin; Wu, Xianghua; Wang, Huijie; Wang, Kai; Lu, Haijiao; Dong, Huishu; Chu, Tianqing; Wang, Jialei

Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (ALK) rearrangements and co-existing alterations-a retrospective cohort study

阿来替尼治疗伴有不同间变性淋巴瘤激酶(ALK)重排和共存改变的肺腺癌患者的疗效——一项回顾性队列研究

Li, Jiaqi; Huang, Kuofang; Ji, Hao; Qian, Jialin; Lu, Haijiao; Zhang, Yanan; Russo, Alessandro; Romero, Atocha; Urbanska, Edyta Maria; Tabbò, Fabrizio; Zhao, Xiaoyu; Chu, Tianqing